Kureha Chemical Industry Company, Limited

Kureha Kagaku Kogyo Kabushiki Kaisha

Other

Koichi Niimura

Takao Ando

Chikao Yoshikumi

Yuko Ikeda

Takayoshi Fujii

Masahiko Fujii

Koju Watanabe

Takako Kawabe

Kenichi Matsunaga

Akira Kato

Yoshiharu Oguchi

Tsutomu Wada

Kenji Bannai

Tsuyoshi Saitoh

Takao Furusho

Kenichi Saito

Shigeaki Muto

Toyohiko Nitta

Kiyonori Umekawa

Junko Miyagawa

Minoru Ohara

Sigemi Tomiyama

Toshimitsu Niwa

Masaaki Takahashi

Akihiko Kanno

Kunitaka Hirose

Norifumi Sugita

Junji Kakuchi

Minoru Oohara

Toru Yamazaki

Yuji Maeda

Tsuyoshi Saito

Sachiko Yamada

Hiroshi Maruoka

Kenji Fukushima

Chondroprotective agents

The disclosure describes a pharmaceutical composition comprising an aromatase-inhibiting effective amount of a compound selected from the group consisting of compounds of the formula (I): ##STR1## including their stereoisomers and salts thereof, wherein R.sup.1 is halogen or phenyl; m is 0, 1, 2 or 3; k and n each are independently 0, 1 or 2; R.sup.2 and R.sup.3 each are independently H or OH; R.sup.6 and R.sup.7 each are independently H or C.sub.1-4 alkyl; R.sup.8 and R.sup.9 each are H or R.sup.8 and R.sup.9 form --C(R.sup.4) (R.sup.5)--C(R.sup.11) (R.sup.12)-- bond wherein R.sup.4, R.sup.5, R.sup.11 and R.sup.12 each are independently H or C.sub.1-4 alkyl; Y is N or CH; and R.sup.10 is H or halogen, or R.sup.10 combines with R.sup.2 to form --O-- bond, with proviso that if R.sup.8 and R.sup.9 form --C(R.sup.4) (R.sup.5)--C(R.sup.11) (R.sup.2)-- bond, R.sup.3, R.sup.6 and R.sup.7 each are H, and k and n each are 1, then R.sup.2 and R.sup.10 form --O-- bond, and a pharmaceutically acceptable carrier or diluent.

Aromatase-inhibiting composition containing azole derivative

A compound of the formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are, independently, a hydrogen atom, a monosaccharide residue, a protected monosaccharide residue, or a protecting group for hydroxyl group, but at least one of R.sup.1 and R.sup.2 is a monosaccharide residue or a protected monosaccharide residue, and R.sup.3 is a hydrogen atom, a hydroxyl group, an alkyl group, an aryl group, or an aralkyl group, with the proviso that (1) when R.sup.1 and R.sup.2 are glucose residues at the same time, R.sup.3 is not a hydrogen atom, (2) when R.sup.1 is a hydrogen atom, an acetyl group or a benzyl group and R.sup.2 is a glucose residue, an acetylated glucose residue, or acetalized glucose residue, R.sup.3 is not a hydrogen atom, or (3) when R.sup.1 is a glucose residue and R.sup.2 is a hydrogen atom, R.sup.3 is not a hydrogen atom or a salt thereof is disclosed.

Esculetin derivatives and method for manufacture thereof, use thereof,

A compound of the formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are, independently, --CON(R.sup.4)R.sup.5, or a monosaccharide, or acylated monosaccharide group, with the proviso that at least one of R.sup.1 and R.sup.2 is --CON(R.sup.4)R.sup.5, and R.sup.4 and R.sup.5 are, independently, a hydrogen atom, or a hydroxyl, alkyl, aryl, or aralkyl group, or R.sup.4 and R.sup.5 together with the nitrogen atom attached thereto form a 3- to 7-membered saturated cycloaliphatic amino group, and R.sup.3 is a hydrogen atom, or a hydroxyl, alkyl, aryl, aralkyl, or --COOR.sup.8 group, and R.sup.3 is at 3- or 4-position, and R.sup.8 is a hydrogen atom or an alkyl group, or a salt thereof is disclosed. The compound has a function to inhibit a matrix metalloproteinase.

Esculetin derivatives, method for manufacture thereof, and

The disclosure describes a pharmaceutical composition comprising an aromatase-inhibiting effective amount of a compound selected from the group consisting of compounds of the formula (I): ##STR1## including their stereoisomers and salts thereof, wherein R.sup.1 is halogen or phenyl; m is 0, 1, 2 or 3; k and n each are independently 0, 1 or 2; R.sup.2 and R.sup.3 each are independently H or OH; R.sup.6 and R.sup.7 each are independently H or C.sub.1-4 alkyl; R.sup.8 and R.sup.9 each are H or R.sup.8 and R.sup.9 form --C(R.sup.4) (R.sup.5)--C(R.sup.11) (R12)-- bond wherein R.sup.4, R.sup.5, R.sup.11 and R.sup.12 each are independently H or C.sub.1-4 alkyl; Y is N or CH; and R.sup.10 is H or halogen, or R.sup.10 combines with R.sup.2 to form --O-- bond, with proviso that if R.sup.8 and R.sup.9 form --C (R.sup.4) (R.sup.5)--C(R.sup.11) (R.sup.12)-- bond R.sup.3, R.sup.6 and R.sup.7 each are H, and k and n each are 1, then R.sup.2 and R.sup.10 form --O-- bond, and a pharmaceutically acceptable carrier or diluent.

A chromone derivative of the formula (I): ##STR1## wherein R.sup.11 is a pyrazolyl, pyrrolyl, triazolyl, benzotriazolyl, benzimidazolyl, indazolyl, or indolyl group, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 is independently a hydrogen or halogen atom, or a hydroxy or alkoxy group, or an alkoxy group substituted with one or more alkoxy groups, and X is an oxygen or sulfur atom, or a salt thereof is disclosed. The chromone derivative inhibits the activity of matrix metalloproteinase.

Chromone compounds, pharmaceutical compositions containing the same, and

A chondroprotective agent comprising a flavonoid compound of the general formula (I): ##STR1## wherein R.sup.1 to R.sup.9 are, independently, a hydrogen atom, hydroxyl group, or methoxyl group and X is a single bond or a double bond, or a stereoisomer thereof, or a naturally occurring glycoside thereof is disclosed. The above compound strongly inhibits proteoglycan depletion from the chondrocyte matrix and exhibits a function to protect cartilage, and thus, is extremely effective for the treatment of arthropathy.

For determining 3-deoxyglucosone derivatives which are intermediate metabolites of the Maillard reaction in body fluids such as blood, urine, serum, plasma and the like in gas chromatography/mass spectrometry, .sup.13 C-labelled compounds or .sup.14 C-labelled compounds are useful as an internal standard substance. More specifically, 3-deoxyglucosone derivatives having the formula (I): ##STR1## wherein *C is .sup.13 C or .sup.14 C, X is O or N--OR wherein R is Me, Et or H, and Y is SiMe.sub.3 or SiMe.sub.2 tBu, and their production are provided. The measurement of 3-deoxyglucosone derivatives is useful in diagnosing diseases such as diabetes and diseases complicated with diabetes, including diabetic nephrosis, various renal disorders, renal insufficiency, metabolic diseases of carbohydrate and the like.

3-deoxyglucosone derivatives

Conjugates of the formula ##STR1## are prepared by reacting an estradiol derivative with a compound of the formula: ##STR2## in the presence of thionyl chloride or a metal hydride at -30.degree. to 150.degree. C. for 3 minutes to 48 hours and then recovering and purifying the product.

Estradiol derivative-alkylating agent conjugate with reduced hormonal

3-Deoxyglucosone derivatives and method for determining the same

A chondroprotective agent comprising a carboxylic acid compound of the general formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are, independently, a hydrogen atom or an alkyl group of 1 to 6 carbon atoms, or a cis- or trans-isomer thereof, or a pharmaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable carrier is disclosed. The above compound strongly inhibits proteoglycan depletion from the chondrocyte matrix and exhibits a function to protect cartilage, and thus, is extremely effective for the treatment of arthropathy.

Method for measuring 3-deoxyglucosone derivatives in a sample

A novel imidazole derivative of the formula (I): ##STR1## wherein X.sub.1 is a chlorine or fluorine atom, or a hydroxy group or a salt thereof, and a pharmaceutical composition containing the same as the active ingredient.

Imidazole derivative, and pharmaceutical composition

Estradiol derivatives of the formula: ##STR1## wherein R.sup.1 is C.sub.1-4 alky or C.sub.1-4 alkoxy; R.sup.2 is acyl or benzyl; m is an integer of 1 to 3; n is an integer of 1 to 3; and X is hydroxy or halogen are useful as tumor growth inhibiting agents.

Estradiol derivative and growth inhibiting composition thereof

A method of inhibiting aromatase, comprising administering to a mammal in need thereof a pharmaceutical composition comprising an effective aromatase inhibiting amount of a compound of the formula (I): ##STR1## wherein X.sub.1 is a chlorine or fluorine atom, or a hydroxy group, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Method of inhibiting aromatase

Growing community of inventors

Saitama, Japan

Koichi Niimura